|Bid||213.90 x 0|
|Ask||214.20 x 0|
|Day's range||213.90 - 219.30|
|52-week range||154.10 - 245.40|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||24.73|
|Earnings date||19 Jul 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||247.25|
Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Apellis' (APLS) earnings missed estimates in the first quarter of 2022, while revenues surpassed expectations.
Swedish Orphan Biovitrum (Sobi) on Thursday reported a smaller-than-expected first-quarter operating profit and said sales grew in emerging markets for its drug Kineret for the treatment of COVID-19. The rare disease drugmaker's operating profit fell to 776 million crowns ($78.6 million) from 1.03 billion and missed the 1.16 billion expected by analysts polled by Refinitiv. The group, which sells drugs targeted at haemophilia, autoimmune diseases, metabolic diseases and cancer supportive care, booked restructuring costs of 507 million and a 157 million provision for expected credit losses in Russia.